Ask AI
ProCE Banner Activity

TROP2-Directed Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer: Current Use in Clinical Practice and Future Directions

Podcast Episodes

In this episode, experts discuss the available efficacy and safety evidence along with their experiences with and strategies for integrating TROP2-directed antibody-drug conjugates into the management of patients with advanced NSCLC, with an emphasis on EGFR-mutant disease and a look at future therapeutic directions on the horizon. 

Released: April 14, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity has been designed to meet the educational needs of oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals involved in the management of patients with NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the significance of TROP2 expression in NSCLC and the therapeutic rationale for targeting TROP2 with antibody–drug conjugates

  • Compare and contrast potential indications, efficacy, and toxicity profiles among available and investigational agents targeting TROP2 in NSCLC

  • Analyze and integrate TROP2 ADCs for patients with NSCLC based on a comprehensive understanding of available clinical data and expert recommendations

  • Design a tailored supportive care plan to manage treatment-related AEs in patients receiving TROP2–targeted therapy, emphasizing QoL and patient comfort

Disclosure

Primary Author

Matthew Gubens, MD, MS, FASCO: consultant/advisor/speaker: AstraZeneca, Bicycle, Bristol Myers Squibb, Cardinal Health, Catalyst, Foresight, Genentech/Roche, Johnson & Johnson, Natera, Nuvalent, OncoHost, Regeneron; researcher (paid to institution): Amgen, Johnson & Johnson, Merck, Trizell.

Helena Yu, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Taiho, Takeda; researcher (paid to institution): AstraZeneca, Cullinan, Daiichi Sankyo, Janssen, SystImmune.